Evidence map›Paper›PMID 38982006›Full record

ArticleAAPS PharmSciTech2024

Pharmacokinetics and Histotoxic Profile of a Novel Azithromycin-Loaded Lipid-Based Nanoformulation.

Aziz Ur Rahman, Munasib Khan, Mir Azam Khan, Maqsood Ur Rehman, Abdullah, Saeed Ahmed

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aziz Ur RahmanDepartment of Pharmacy, University of Malakand, Chakdara Dir (Lower), Khyber Pakhtunkhwa, Chakdara, 18800, Pakistan. aziz.rahman@uom.edu.pk.ORCID http://orcid.org/0000-0002-5014-7903
Munasib KhanDepartment of Pharmacy, University of Malakand, Chakdara Dir (Lower), Khyber Pakhtunkhwa, Chakdara, 18800, Pakistan.
Mir Azam KhanDepartment of Pharmacy, University of Malakand, Chakdara Dir (Lower), Khyber Pakhtunkhwa, Chakdara, 18800, Pakistan.
Maqsood Ur RehmanDepartment of Pharmacy, University of Malakand, Chakdara Dir (Lower), Khyber Pakhtunkhwa, Chakdara, 18800, Pakistan.
AbdullahDepartment of Pharmacy, University of Malakand, Chakdara Dir (Lower), Khyber Pakhtunkhwa, Chakdara, 18800, Pakistan.
Saeed AhmedDepartment of Pharmacy, University of Malakand, Chakdara Dir (Lower), Khyber Pakhtunkhwa, Chakdara, 18800, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azithromycin traditional formulations possesses poor oral bioavailability which necessitates development of new formulation with enhanced bioavailability of the drug. The objective of current research was to explore the kinetics and safety profile of the newly developed azithromycin lipid-based nanoformulation (AZM-NF). In the in-vitro study of kinetics profiling, azithromycin (AZM) release was assessed using dialysis membrane enclosing equal quantity of either AZM-NF, oral suspension of azithromycin commercial product (AZM-CP), or azithromycin pure drug (AZM-PD) in simulated intestinal fluid. The ex-vivo study was performed using rabbit intestinal segments in physiological salts solution in a tissue bath. The in-vivo study was investigated by oral administration of AZM to rabbits while taking blood samples at predetermined time-intervals, followed by HPLC analysis. The toxicity study was conducted in rats to observe histopathological changes in rat's internal organs. In the in-vitro study, maximum release was 95.38 ± 4.58% for AZM-NF, 72.79 ± 8.85% for AZM-CP, and 46.13 ± 8.19% for AZM-PD (p < 0.0001). The ex-vivo investigation revealed maximum permeation of 85.68 ± 5.87 for AZM-NF and 64.88 ± 5.87% for AZM-CP (p < 0.001). The in-vivo kinetics showed C

Indexed as

AzithromycinBiological AvailabilityLipidsNanoparticlesAdministration, OralAnimalsAnti-Bacterial AgentsChemistry, PharmaceuticalDrug CarriersDrug LiberationMaleRabbitsRatsAnti-Bacterial AgentsAzithromycinDrug CarriersLipidsAzithromycinEx-vivo permeabilityIn-vitro release kineticsIn-vivo bioavailability studiesKinetics profilingLipid-based nanoformulation

Identifiers

PMID38982006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.